cyrilzakka/clinical-trials huggingface dataset:
BAI-BACE for Advanced Lung Squamous Cell Carcinoma

Bronchial arterial infusion plus bronchial arterial chemoembolization (BAI-BACE) has been reported as non-first-line therapy to treat lung cancer in many hospitals in China. BAI, which uses chemotherapeutic drugs directly injected into the tumor and achieved a high concentration in a short time to kill the tumor. Then BACE could seal off the tumor vessels. In this study, we aim to describe the efficacy and safety of BAI-BACE as non-first-line for advanced lung squamous cell carcinoma.

This study is a multicenter, interventional study to explore the efficacy, safety of BAI-BACE as non-first-line therapy for advanced central squamous cell carcinoma. Lung cancer is the leading cause of cancer-related death worldwide. Owing to the insidious symptom, most patients (about 75 %) are diagnosed at the advanced stage of the disease and, thus, cannot undergo resection. The central squamous cell carcinoma accounts for 25% of all cases of lung cancer. The first-line standard treatment for advanced central squamous cell carcinoma is combined chemoradiotherapy, and chemoradiotherapy is usually as the second-line. However, treatment failure is noted in many patients, and those patients often face the limited therapy choice and poor prognosis. Bronchial arterial infusion plus bronchial arterial chemoembolization (BAI-BACE) has been reported to treat lung cancer in many hospitals in China. BAI, which use chemotherapeutic drugs directly injected into the tumor and achieved a high concentration in a short time to kill the tumor. Then BACE could seal off the tumor vessels. The systemic toxicity of this surgery is low and tolerable. This study will provide clinical evidence that BACE-BAI will provide survival benefit for patients with advanced central squamous cell carcinoma.

Eligibility Criteria:
Inclusion Criteria:

1. Squamous cell carcinoma diagnosed by pathology, and central location by imaging;
2. Age 18-80;
3. Patients failed to the standard first-line or second-line treatment;
4. Tumors limited in the chest;
5. Tumors were fed by bronchial artery through CTA reconstruction;
6. Patents received PD-1 inhibitor or not were also included;
7. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-2;
8. Images within 2 weeks before inclusion;
9. Life expectancy more than 3 months;
10. Agreed to participated in this clinical trial;
11. Hemameba ≥3.0 x109/L, neutrophil ≥1.5x109/L, hemoglobin≥10.0 g/L, platelet≥100x 109/L, ALT; AST; bilirubin ≤1.5-fold normal, GFR≥60ml/min.

Exclusion Criteria:

1. Contraindication of BAI or BACE;
2. Under 18 years or over 75 years;
3. extra-chest metastases;
4. Receiving other antitumor treatment;
5. Severe infection or pregnancy;
6. Severe Pulmonary fibrosis and pulmonary artery;
7. liver, kidney or poor physical conditions;
8. Severe pleural effusion or pericardial effusion;
9. Life expectancy less than 3 months.
Application of HBV Rapid Tests as a Tool for Wide-Use Screening

With over 280 000 chronic carriers, 2,500 new annual cases and 1,300 deaths each year, hepatitis B is currently a frequent and potentially severe disease in France, despite efforts towards prevention and effective care.

In terms of prevention, France has very low immunization coverage (27.7%) and a high percentage of people ignoring HBV status (55%), leading to a delay in care. This is partly explained by poor knowledge of hepatitis B infection in the general population and an underestimation of the health impact of hepatitis B by doctors and health officials. Until recently, there have been no national guidelines governing its implementation (which is variable depending on the structures where screening is performed) and an insufficient evaluation of screening practices. Thus, data on the severity of liver disease, indications for treatment of HBV-infected patients and data on the use of vaccination for nonimmunized people are scarce. Furthermore, while HIV rapid tests are beginning to be used more widely, particularly to address the issue of people who do not come back and collect their results and to better adapt "counselling", their usefulness to detect of hepatitis B virus has not been evaluated to date.

The main objective of the Optiscreen B Study is to determine the benefit, if any, of using rapid tests as a screening tool to improve diagnosis, care and prevention of hepatitis B. Individuals risk of HBV-infection will be randomized into 2 groups, one group for which screening will be performed by usual serological test and a second group for which screening will be based on rapid tests. Centers will be selected to represent a diverse range of health centers whose aims include screening, prevention and/or vaccination.


Eligibility Criteria:
Inclusion Criteria:

* Born in a country of middle or high HBV endemicity
* Parents born in a country of middle or high HBV endemicity
* Travellers or residents from a country of middle or high HBV endemicity
* Blood, organ, tissue, sperm, and/or ovary donners or candidate donners.
* Health-care workers suspected of coming into direct contact with an HBV-infected individual and/or exposed to blood or any biological products from an HBV-infected individual
* Close contact with HBsAg-positive individuals (living in the same household, sexual partner, sharing needles, etc.)
* Individuals with accidental exposure to HBV
* Individuals with multiple sexual partners
* Men who have sex with men
* Pregnant women
* Hemodialysis
* Individuals requiring immunosuppressive therapy
* Individuals with persistently elevated transaminase levels
* HIV-positive
* Intravenous drug users

Exclusion Criteria:

* Age \<18 years old
* Not capable of providing informed consent
* Already participated in a multi-center validation of HBV rapid tests
* Having, in their possession, irrefutable results of a prior test for hepatitis B virus
Home Blood Pressure-guided Antihypertensive Intervention for Elderly (HBP-GUIDE) Study

The purpose of this study is to determine whether blood pressure control by home blood pressure monitoring exerts beneficial cardioprotective effects rather than by clinic blood pressure monitoring in elderly patients.

Home blood pressure (BP) measurement has been reported to be closely correlated with target organ damage and appears to be a prognostic indicator with respect to cardiovascular mortality and cardiovascular events. However, whether BP control by home BP monitoring exerts cardioprotective effects rather than by clinic BP monitoring in elderly patients remains unknown. In this study, a total of 500 elderly patients diagnosed with essential hypertension will be randomly divided into 2 groups; target BP level, home SBP \<135 mmHg and home DBP \<85 mmHg (home BP control group), clinic SBP \<140 mmHg and clinic DBP \<90 mmHg (clinic BP control group). Olmesartan at doses of 20 mg/day will be administered and increased up to 40 mg, if antihypertensive effect is inadequate. Study visits will be made bimonthly for at least 1 year. The antihypertensive and cardioprotective effects including systemic levels of C-reactive protein and inflammatory cytokines, and arterial stiffness will be compared between the two groups.

Eligibility Criteria:
Inclusion Criteria:

* Outpatients aged over 65 years and less than 80 years
* Patients with a stable seated systolic blood pressure of ≥ 140 mmHg or diastolic blood pressure of ≥ 90 mmHg at two visits within 8 weeks
* Patients with a stable seated systolic blood pressure of ≥ 135 mmHg or diastolic blood pressure of ≥ 85 mmHg at home (home blood pressure is measured every morning within 1 h of waking, and defined as the mean of 3 days measurement within 8 weeks)

Exclusion Criteria:

* Patients with secondary hypertension or malignant hypertension
* Patients with a stable seated systolic pressure of ≥ 180 mmHg or diastolic pressure of ≥ 110 mmHg
* Patients with renal dysfunction with a serum creatinine level of ≥ 2 mg/dl
* Patients with liver dysfunction
* Patients with a history of hypersensitivity to angiotensin II receptor blockade
* Patients with a history of myocardial infarction within 6 months prior to enrolment in the study
* Patients who underwent coronary arterioplasty within 6 months prior to enrolment in the study or patients who will undergo coronary arterioplasty within 6 months after entry
* Patients with heart failure
* Patients with a history of cerebrovascular disorder
* Other patients who are judged to be inappropriate for the study by the investigator
Syndecan 1 as Biomarker for Inflammation

The aim of the study is to evaluate the soluble biomarker syndecan-1 (sSdc1) taken from venous blood of patients with infectious intestinal diseases such as Clostridium difficile-associated colitis, bacterial colitis, Norovirus enteritis and Crohn´s disease or ulcerative colitis. The level of sSdc1 will be compared with disease activity in patients with active inflammation and with disease in remission. Secondary objectives were the assessment of correlation of the above-mentioned factors with the CRP value. Subjects will be volunteers. Blood will be taken as part of the routine clinical work-up after the written agreement blood and sSdc1-level will be assessed using a human-specific sSdc1 ELISA assay. In addition, the subjects are asked to answer a short questionnaire. The study is designed as a prospective, comparative cohort study.


Eligibility Criteria:
Inclusion Criteria:

* Subject with at least 18 years of age
* able to give informed consent
* healthy volunteer or inflammatory bowel condition (inflammatory bowel disease, infectious colitis)

Exclusion Criteria:

* not able to give informed consent
The Effects of Spinal Anesthesia on ED50 and BIS50 of Etomidate for the Loss of Consciousness

The purpose of this study is to investigate the effect of spinal anesthesia on ED50 and BIS50 of etomidate for the loss of consciousness (LOC) by using up-and-down method.The hypothesis was that spinal anesthesia could significantly reduce the etomidate bolus dose for the LOC and could also achieve hemodynamic stability during anesthesia induction.

The combination of spinal with general anesthesia has been demonstrated to provide many clinically relevant advantages, however, this technique often experiences hypotension and bradycardia in the induction period of combined anesthesia. Etomidate is a carboxylated imidazole-derived hypnotic, and it is the most cardiovascularly stable intravenous induction drug, with the possible exception of ketamine. Meanwhile, the previous and our studies have been reported that spinal anesthesia has a direct sedative effect on animals and humans, and it markedly reduces the dose of hypnotic agents. To date, there is no dose-ranging study on the effect of spinal anesthesia on dosage of etomidate for the loss of consciousness (LOC). In the present study, investigators aim to investigate the effect of spinal anesthesia on the median effective dose (ED50) and the BIS value (BIS50) of etomidate at which 50% of patients lose consciousness compared to etomidate alone by using up-and-down method.

Patients were randomly allocated to one of two groups: only etomidate in group E (n=27) and spinal anesthesia combined with etomidate in group SE (n=21) using a randomization table. Patients in the SE group received spinal anesthesia first, and bilateral sensory anesthesia level was confirmed to remain at the T4-T6 level. After confirmation of the level of sensory anesthesia, the administration of etomidate was conducted. The etomidate (Nhwa Pharmaceutical, Jiangsu, China) starting dose of E group and SE group is 0.105 mg/kg and 0.089mg/kg, respectively. The dose of etomidate used for next patient was determined according to the response of the previously tested patient using the up-and-down method. If the patient lose consciousness, the dose of etomidate was reduced by one dose gradient for the next patient, and if didn't lose consciousness, the dose of etomidate was increased by one dose gradient (one dose gradient is r=1:0.85, that is, the ratio of high dose/low dose which are adjacent two doses). The testing of different dose levels of etomidate continued on consecutive randomised patients until a sample size of seven crossover points from "conscious" to "LOC" was reached

Eligibility Criteria:
Inclusion Criteria:

* ASA physical status I-II
* Body mass index (BMI) between 18.0 and 24.5 kg/m2
* Undergoing short elective laparotomy procedures, hysteroscopic and vaginal operation

Exclusion Criteria:

* Contraindication to spinal anesthesia
* Hearing loss
* History of cardiovascular disease, psychiatric and central nervous system diseases
* Hepatic or renal dysfunction
* Severe diabetes or hyperkalemia
* History of drug and alcohol abuse
* An allergy to amide local anesthetics or etomidate
* Adrenocortical hypofunction
Invasive Measurement of Axial Plaque Stress, the Pilot Study

In this study, the investigators sought to evaluate the feasibility of estimating external hemodynamic stress acting plaque with the use of invasively measured hemodynamic data from pressure wire pullback tracing.

In addition, the investigators will also evaluate detailed plaque geometry and vulnerability using optical coherence tomography along with the hemodynamic stress.

It has been well known that mechanism of acute coronary syndrome is plaque rupture and occlusion of coronary artery by this plaque rupture. Although current risk assessment for plaque rupture have mainly focused on evaluation of plaque vulnerability. However, according to the general mechanism of material failure, plaque rupture occurs whenever the external hemodynamic stress exceeds the durability of the plaque.

Recently, we evaluated the axial plaque stress, which is axial component of total traction acting on the plaque, and showed that the axial plaque stress possess significantly higher magnitude than previously known wall shear stress.

However, the axial plaque stress in our previous research was measured with computational flow dynamics analysis using coronary artery model from coronary CT angiography.

In this study, we sought to evaluate the feasibility of estimating external hemodynamic stress acting plaque with the use of invasively measured hemodynamic data from pressure wire pullback tracing.

In addition, we will also evaluate detailed plaque geometry and vulnerability using optical coherence tomography along with the hemodynamic stress.

Eligibility Criteria:
Inclusion Criteria:

* 1. Patients with angina pectoris who are scheduled to do invasive coronary angiography.
* 2. Patients who have moderate (40-70%) stenosis at proximal or mid-portion of major coronary arteries.
* 3. Pressure wire pullback tracing and Optical Coherence Tomography ware successfully performed

Exclusion Criteria:

* 1. Stenosis at distal coronary or small vessel.
* 2. Patients who don't have moderate (40-70%) stenosis at proximal or mid-portion of major coronary arteries. Confirmed by invasive coronary angiography.
* 3. Inadequate quality of Optical Coherence Tomography
* 4. No data of Fractional Flow Reserve or Pressure wire pullback tracing or inadequate data of Fractional Flow Reserve or Pressure wire pullback tracing
Effects of Acleara Needle Insert on Acne

This prospective, open-label study will be conducted in 15 healthy subjects per clinical site ages 14 or older who meet the inclusion/exclusion criteria. Each subject may have up to 5 lesions treated on the face, chest or back with the Acleara insert. Subjects will receive up to 3 follow up visits and evaluated for improvement in acne lesions and monitored for any adverse events.


Eligibility Criteria:
Inclusion Criteria:

* Subjects \>14 years of age
* Subject has mild to moderate acne vulgaris on the face, chest or back.
* Subject has one or more inflammatory acne lesions on face, chest or back.
* Willingness to participate in the study
* Informed consent agreement signed by the subject
* Willingness to follow the treatment schedule and post treatment care requirements
* Willingness to remain on current acne therapy as directed by the Investigator.

Exclusion Criteria:

* Subject has an infection or other dermatologic condition (aside from acne) in the area to be treated
* Subject is immunosuppressed
* Subject is unable to comply with treatment or follow-up visits
* Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.
A Multicenter Registry Study of Aneurysmal SAH

Firstly, this study aims at clarifying the current situation of Emergency treatment of aneurysmal subarachnoid hemorrhage (SAH) in China, and analyzing the influencing factors contributing to transport delay, so as to improve the efficiency of emergency treatment; Secondly, comparison and analysis of different surgical treatment of aneurysmal SAH would be undertook, so as to improve the diagnosis and treatment of aneurysmal SAH.


Eligibility Criteria:
Inclusion Criteria:

* patients presented with subarachnoid hemorrhage on CT or lumbar puncture.
* the intracranial hemorrhage was caused by rupture of aneurysm and was confirmed on CTA、MRA or DSA.
* patients willing to participate in this clinical trial and attach to regular follow up.

Exclusion Criteria:

* intracranial aneurysm correlating to AVM.
* dissection, false, traumatic and infectious aneurysms.
* the rupture of the aneurysm can not be confirmed on CTA、MRA or DSA.
Active Learning and EBP Competency in Undergraduate Physiotherapy

This study aims to evaluate the effect of an active learning-based educational intervention on competencies related to evidence-based practice (EBP) in undergraduate physiotherapy students. The intervention was embedded within a four-month Research Methods course and focused on small group activities involving literature search, critical appraisal, oral presentations, and formative assessment through rubrics.

The study follows a pre-post quasi-experimental design without a control group. Primary outcomes include students' beliefs, attitudes, perceived skills, and frequency of EBP application, assessed through a custom-developed and validated questionnaire. Secondary outcomes include academic engagement, measured using the Utrecht Work Engagement Scale - Student Version (UWES-S), and student satisfaction with the educational approach, measured using the Student Outcomes Survey. Data were collected at baseline, post-intervention, and one week after course completion.

This quasi-experimental study without a control group will be conducted at the Universidad Nacional de La Matanza (UNLaM), Argentina, between March and July 2025. The study aimed to evaluate the effect of an educational intervention based on active learning strategies on evidence-based practice (EBP) competencies among physiotherapy students.

The intervention was implemented as part of a four-month Research Methods course and included weekly group-based activities such as literature retrieval, critical appraisal, oral presentations, peer feedback, and structured assessments using rubrics. The course aimed to strengthen students' beliefs, attitudes, perceived skills, and frequency of use related to EBP.

Outcomes were assessed using a custom-developed and validated questionnaire covering four domains and key competencies in EBP. Secondary outcomes included academic engagement, measured with the Utrecht Work Engagement Scale - Student Version (UWES-S), and student satisfaction, assessed through the Student Outcomes Survey. Data collection occurred at baseline, at the end of the course, and one week after completion. The study followed TREND reporting guidelines and was approved by the institutional research ethics committee at UNLaM.

Eligibility Criteria:
Inclusion Criteria:

* Undergraduate students enrolled in the Research Methods course at the Universidad Nacional de La Matanza during the March-July 2024 term.
* Provided written informed consent.
* Attended at least 80% of course sessions.

Exclusion Criteria:

* Students who withdrew from the course before completion of the follow-up period.
* Incomplete or missing baseline or final evaluation data.
Creation of a PBRN to Study Healthcare Delivery to a Transitioning Community

The purpose of this study is the creation of a PBRN that will comprise primary care providers, community health organizations, community advocates and a research core of two academic institutions in order to study the healthcare needs of a rapidly growing immigrant population.

The Carolinas Healthcare System (CHS) Department of Family Medicine in partnership with The University of North Carolina at Charlotte (UNCC) Geography Department have initiated a primary-care practice-based research network (PBRN) bringing together primary care physicians, local academic centers, and community organizations to study healthcare delivery to the burgeoning Hispanic population in Charlotte, North Carolina. CHS has created six primary care ambulatory clinics that serve as teaching centers and as "safety-net" practices for disadvantaged patients within the community. Despite many similarities between the clinics, including a shared informatics system, no research network currently exists. Creation of the proposed PBRN would allow the participating primary care providers to evaluate the community they serve, determine disparities in healthcare access and delivery, and to elucidate the impact of current services on the community. In addition, the PBRN brings together two academic institutions with prior experience implementing the community-oriented primary care model and the use of Geographic Information Systems tools for evaluating communities and understanding health care access.

The neighborhoods surrounding the CHS clinics have changed drastically over the past two decades secondary to a marked increase in Hispanic immigration to the area. This growth has produced an increasing demand on local healthcare providers. Our goal is to utilize the newly created research network to better understand healthcare delivery to the transitioning Hispanic population and thereby maximize quality of care and the efficacy of its delivery. Community organizations will be involved from the outset to allow community-based participation in the research design and overall goals. Creation of this initial PBRN will be used to lay the groundwork for expansion into other primary care practices and to seek funding for further research initiatives to improve community health.

Eligibility Criteria:
Inclusion Criteria:

* Hispanic